Home » Influenza Vaccination Market
Influenza Vaccination Market
Published date: Dec 2021 •Formats:
Request Sample Schedule a Call

Global Influenza Vaccination Market By Type (by Technology, Egg Based, Cell Culture, Recombinant, by Vaccines, Fluzone, Flumist, Fluvirin, Fluvax, Market Size Split by Application, Hospitals, and Research Organizations), By Application (application1 application2, ), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • Published date: Dec 2021
  • Report ID: 67915
  • Number of Pages: 290
  • Format:
  • keyboard_arrow_up
    • 1. Influenza Vaccination Market Introduction
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
    • 2. Executive Summary
      • 2.1. Key Findings by Major Segments
      • 2.2. Top strategies by Major Players
    • 3. Global Influenza Vaccination Market Overview
      • 3.1. Influenza Vaccination Market Dynamics
        • 3.1.1. Drivers
        • 3.1.2. Opportunities
        • 3.1.3. Restraints
        • 3.1.4. Challenges
      • 3.2. PESTLE Analysis
      • 3.3. Opportunity Map Analysis
      • 3.4. PORTER'S Five Forces Analysis
      • 3.5. Market Competition Scenario Analysis
      • 3.6. Product Life Cycle Analysis
      • 3.7. Opportunity Orbits
      • 3.8. Production Analysis by Region/Company
      • 3.9. Industry chain Analysis
      • 3.10. Marketing Strategy
    • 4. Global Influenza Vaccination Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
      • 4.1. Global Influenza Vaccination Market Analysis by Type: Introduction
      • 4.2. Market Size and Forecast by Region
      • 4.3. by Technology
      • 4.4. Egg Based
      • 4.5. Cell Culture
      • 4.6. Recombinant
      • 4.7. by Vaccines
      • 4.8. Fluzone
      • 4.9. Flumist
      • 4.10. Fluvirin
      • 4.11. Fluvax
      • 4.12. Market Size Split by Application
      • 4.13. Hospitals
      • 4.1 4. Research Organizations
    • 5. Global Influenza Vaccination Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
      • 5.1. Global Influenza Vaccination Market Analysis by Application: Introduction
      • 5.2. Market Size and Forecast by Region
      • 5.3. application1 application2
    • 6. Global Influenza Vaccination Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
      • 6.1. North America
        • 6.1.1. North America Influenza Vaccination Market: Regional Trend Analysis
          • 6.1.1.1. US
          • 6.1.1.2. Canada
          • 6.1.1.3. Mexico
      • 6.2.1. Europe
        • 6.2.1. Europe Influenza Vaccination Market: Regional Trend Analysis
          • 6.2.1.1. Germany
          • 6.2.1.2. France
          • 6.2.1.3. UK
          • 6.2.1.4. Russia
          • 6.2.1.5. Italy
          • 6.2.1.6. Spain
          • 6.2.1.7. Rest of Europe
      • 6.3. Asia-Pacific
        • 6.3.1. Asia-Pacific Influenza Vaccination Market: Regional Trend Analysis
          • 6.3.1.1. China
          • 6.3.1.2. Japan
          • 6.3.1.3. Korea
          • 6.3.1.4. India
          • 6.3.1.5. Rest of Asia-Pacific
      • 6.4. Latin America
        • 6.4.1. Latin America Influenza Vaccination Market: Regional Trend Analysis
          • 6.4.1.1. Brazil
          • 6.4.1.2. Argentina
          • 6.4.1.3. Rest of Latin America
      • 6.5. Middle East and Africa
        • 6.5.1. Middle East and Africa Influenza Vaccination Market: Regional Trend Analysis
          • 6.5.1.1. GCC
          • 6.5.1.2. South Africa
          • 6.5.1.3. Israel
          • 6.5.1.4. Rest of MEA
    • 7. Global Influenza Vaccination Market Competitive Landscape, Market Share Analysis, and Company Profiles
      • 7.1. Market Share Analysis
      • 7.2. Company Profiles
      • 7.3. Abbott (U.S.)
        • 7.3.1. Company Overview
        • 7.3.2. Financial Highlights
        • 7.3.3. Product Portfolio
        • 7.3.4. SWOT Analysis
        • 7.3.5. Key Strategies and Developments
      • 7.4. AstraZeneca (Europe)
        • 7.4.1. Company Overview
        • 7.4.2. Financial Highlights
        • 7.4.3. Product Portfolio
        • 7.4.4. SWOT Analysis
        • 7.4.5. Key Strategies and Developments
      • 7.5. BioCryst Pharmaceuticals#Inc. (U.S.)
        • 7.5.1. Company Overview
        • 7.5.2. Financial Highlights
        • 7.5.3. Product Portfolio
        • 7.5.4. SWOT Analysis
        • 7.5.5. Key Strategies and Developments
      • 7.6. Novartis AG (Europe)
        • 7.6.1. Company Overview
        • 7.6.2. Financial Highlights
        • 7.6.3. Product Portfolio
        • 7.6.4. SWOT Analysis
        • 7.6.5. Key Strategies and Developments
      • 7.7. DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific)
        • 7.7.1. Company Overview
        • 7.7.2. Financial Highlights
        • 7.7.3. Product Portfolio
        • 7.7.4. SWOT Analysis
        • 7.7.5. Key Strategies and Developments
      • 7.8. GlaxoSmithKline plc. (Europe)
        • 7.8.1. Company Overview
        • 7.8.2. Financial Highlights
        • 7.8.3. Product Portfolio
        • 7.8.4. SWOT Analysis
        • 7.8.5. Key Strategies and Developments
      • 7.9. Hualan Biological Engineering Inc (Asia Pacific)
        • 7.9.1. Company Overview
        • 7.9.2. Financial Highlights
        • 7.9.3. Product Portfolio
        • 7.9.4. SWOT Analysis
        • 7.9.5. Key Strategies and Developments
      • 7.10. Mitsubishi Tanabe Pharma Corporation (Asia Pacific)
        • 7.10.1. Company Overview
        • 7.10.2. Financial Highlights
        • 7.10.3. Product Portfolio
        • 7.10.4. SWOT Analysis
        • 7.10.5. Key Strategies and Developments
      • 7.11. F. Hoffmann-La Roche Ltd (Europe)
        • 7.11.1. Company Overview
        • 7.11.2. Financial Highlights
        • 7.11.3. Product Portfolio
        • 7.11.4. SWOT Analysis
        • 7.11.5. Key Strategies and Developments
      • 7.12. Sanofi (Europe)
        • 7.12.1. Company Overview
        • 7.12.2. Financial Highlights
        • 7.12.3. Product Portfolio
        • 7.12.4. SWOT Analysis
        • 7.12.5. Key Strategies and Developments
    • 8. Assumptions and Acronyms
    • 9. Research Methodology
    • 10. Contact
    • Abbott (U.S.)
    • AstraZeneca (Europe)
    • BioCryst Pharmaceuticals Inc. (U.S.)
    • Novartis AG (Europe)
    • DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific)
    • GlaxoSmithKline plc. (Europe)
    • Hualan Biological Engineering Inc (Asia Pacific)
    • Mitsubishi Tanabe Pharma Corporation (Asia Pacific)
    • F. Hoffmann-La Roche Ltd (Europe)
    • Sanofi (Europe)
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Influenza Vaccination Market
  • 67915
  • Dec 2021
    • ★★★★★
      ★★★★★
    • (12)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
Find Help
Legal
Explore